RESUMEN
BACKGROUND: The burden of chronic liver disease (CLD) deaths attributable to the hepatitis B virus (HBV) and hepatitis C virus (HCV) remains unknown. Further research is required to elucidate the extent of this burden in the eventual elimination of these diseases. METHODS: Data on liver cancer, cirrhosis, and other CLD among 204 countries and territories between 1990 and 2019 was extracted from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) published in 2019. The Bayesian age-period-cohort model was used to analyze the temporal trend and predict the disease burden by 2030. RESULTS: The number of HCV-related CLD deaths surpassed that of CLD deaths caused by HBV in 2019 (536833 deaths versus 523003 deaths) and is expected to be maintained until 2030 (689124 deaths versus 628824 deaths). East Asia had the highest burden of chronic HBV and HCV infections during the study period. In 2019, the largest age-standardized death rates (ASDR) of CLD deaths caused by HBV and HCV were mainly observed in Western Sub-Saharan Africa (18.75%) and Eastern Sub-Saharan Africa (16.42%), respectively. South Asia and East Asia are predicted to have the highest number of CLD deaths related to HCV and HBV by 2030. Eastern Europe and South Asia show the largest expected increase in disease burden caused by HCV or HBV between 2019 and 2030. No GBD region is projected to achieve the WHO target of a 65% reduction in mortality from chronic HBV and HCV infections by 2030. CONCLUSIONS: Although the mortality of CLD caused by HBV and HCV decreased in the last three decades (from 1990 to 2019), the number of deaths will continue to increase until 2030. Therefore, governments and international organizations need to strengthen the effectiveness of vaccines, screening, and treatment, especially in potential emerging hotspot regions.
Asunto(s)
Salud Global , Hepatitis B Crónica , Hepatitis C Crónica , Humanos , Salud Global/estadística & datos numéricos , Hepatitis C Crónica/mortalidad , Hepatitis C Crónica/epidemiología , Hepatitis B Crónica/mortalidad , Hepatitis B Crónica/epidemiología , Hepatitis B Crónica/complicaciones , Masculino , Femenino , Factores de Riesgo , Persona de Mediana Edad , Adulto , Hepatitis B/mortalidad , Hepatitis B/epidemiología , Carga Global de Enfermedades , Hepatopatías/mortalidad , Hepatopatías/epidemiología , Enfermedad Crónica/epidemiología , Hepatitis C/mortalidad , Hepatitis C/epidemiología , Teorema de Bayes , AncianoRESUMEN
INTRODUCTION: Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. This clinical study aimed to evaluate its antiviral efficacy of ropeginterferon alfa-2b against SARS-CoV-2 infection. METHODS: This is a multicenter, randomized, open-label study. Adult patients with confirmed SARS-CoV-2 infection with initial cycle threshold (Ct) value < 30 and symptom onset within 4 days were enrolled. Eligible patients were randomized in a 2:1 ratio to receive a single 250-µg dose of ropeginterferon alfa-2b subcutaneously plus standard of care (SOC) or to receive SOC alone. The primary endpoint was the proportion of patients with a negative RT-PCR result for SARS-CoV-2 or discharged from the hospital before Day 8. Change in clinical status based on the World Health Organization (WHO) clinical progression scale and pulmonary infiltrations through chest radiograph were also evaluated. RESULTS: A total of 132 patients were enrolled and treated with study medication. Higher percentages of patients who achieved Ct ≥ 30 or were discharged from the hospital were observed on Day 8 and every other time point of assessment, i.e., Days 5, 11, 15, and 22, in the ropeginterferon alfa-2b group compared to the SOC alone group. However, the difference was statistically significant on Day 11 but not on Day 8. The primary endpoint was not met. The ropeginterferon alfa-2b group showed a higher improvement rate in lung infiltration on Day 5 (27.6% vs. 0.0%, p = 0.0087) and a higher improvement rate in WHO clinical progression scores on Day 8 (69.4% vs. 35.3%, p = 0.03) than those in the SOC group. No ropeginterferon alfa-2b-related serious adverse event was observed. CONCLUSION: Our data show that ropeginterferon alfa-2b with SOC shortened the duration of SARS-CoV-2 shedding compared with SOC alone. In addition, ropeginterferon alfa-2b as an additional therapy could be beneficial by improving lung infiltration.
RESUMEN
BACKGROUND: Immunomodulatory agents, such as tocilizumab (TCZ), exert promising effects against SARS-CoV-2 infection. However, growing evidence indicates that using TCZ may carry higher risks of secondary bloodstream infection (sBSI). This study determined whether TCZ is associated with an increased risk of sBSI. METHODS: We retrospectively collected the demographic and clinical data of hospitalized patients with SARS-CoV-2 infection from two Taiwanese hospitals. The time-to-incident sBSI in the TCZ users and nonusers was compared using the log-rank test. A multivariate Cox proportional hazards model was performed to identify independent risk factors for sBSI. RESULTS: Between May 1 and August 31, 2021, among 453 patients enrolled, 12 (2.65 %) developed sBSI. These patients were in hospital for longer duration (44.2 ± 31.4 vs. 17.6 ± 14.3 days, p = 0.014). Despite sBSI being more prevalent among the TCZ users (7.1 % vs. 1.6 %, p = 0.005), Kaplan-Meier survival analysis and multivariate Cox proportional hazards model both revealed no significant difference in risks of sBSI between the TCZ users and nonusers [adjusted HR (aHR) = 1.32 (95 % confidence interval (CI) = 0.29-6.05), p = 0.724]. Female sex [aHR = 7.00 (95 % CI = 1.45-33.92), p = 0.016], heavy drinking [aHR = 5.39 (95 % CI = 1.01-28.89), p = 0.049], and mechanical ventilation [aHR = 5.65 (95 % CI = 1.67-19.30), p = 0.006] were independently associated with a higher sBSI risk. CONCLUSION: This real-world evidence indicates that in hospitalized patients with SARS-CoV-2 infection, TCZ does not significantly increase the risk of sBSI.
Asunto(s)
Anticuerpos Monoclonales Humanizados , COVID-19 , Coinfección , Sepsis , Humanos , Femenino , COVID-19/epidemiología , Estudios de Cohortes , Estudios Retrospectivos , SARS-CoV-2 , Tratamiento Farmacológico de COVID-19RESUMEN
Background: The Omicron variant of SARS-CoV-2 is more highly infectious and transmissible than prior variants of concern. It was unclear which factors might have contributed to the alteration of COVID-19 cases and deaths during the Delta and Omicron variant periods. This study aimed to compare the COVID-19 average weekly infection fatality rate (AWIFR), investigate factors associated with COVID-19 AWIFR, and explore the factors linked to the increase in COVID-19 AWIFR between two periods of Delta and Omicron variants. Materials and methods: An ecological study has been conducted among 110 countries over the first 12 weeks during two periods of Delta and Omicron variant dominance using open publicly available datasets. Our analysis included 102 countries in the Delta period and 107 countries in the Omicron period. Linear mixed-effects models and linear regression models were used to explore factors associated with the variation of AWIFR over Delta and Omicron periods. Findings: During the Delta period, the lower AWIFR was witnessed in countries with better government effectiveness index [ß = -0.762, 95% CI (-1.238)-(-0.287)] and higher proportion of the people fully vaccinated [ß = -0.385, 95% CI (-0.629)-(-0.141)]. In contrast, a higher burden of cardiovascular diseases was positively associated with AWIFR (ß = 0.517, 95% CI 0.102-0.932). Over the Omicron period, while years lived with disability (YLD) caused by metabolism disorders (ß = 0.843, 95% CI 0.486-1.2), the proportion of the population aged older than 65 years (ß = 0.737, 95% CI 0.237-1.238) was positively associated with poorer AWIFR, and the high proportion of the population vaccinated with a booster dose [ß = -0.321, 95% CI (-0.624)-(-0.018)] was linked with the better outcome. Over two periods of Delta and Omicron, the increase in government effectiveness index was associated with a decrease in AWIFR [ß = -0.438, 95% CI (-0.750)-(-0.126)]; whereas, higher death rates caused by diabetes and kidney (ß = 0.472, 95% CI 0.089-0.855) and percentage of population aged older than 65 years (ß = 0.407, 95% CI 0.013-0.802) were associated with a significant increase in AWIFR. Conclusion: The COVID-19 infection fatality rates were strongly linked with the coverage of vaccination rate, effectiveness of government, and health burden related to chronic diseases. Therefore, proper policies for the improvement of vaccination coverage and support of vulnerable groups could substantially mitigate the burden of COVID-19.
Asunto(s)
COVID-19 , Enfermedades Cardiovasculares , Humanos , Anciano , COVID-19/epidemiología , SARS-CoV-2 , GobiernoRESUMEN
Our study aims to compare the pandemic resilience index and explore the associated factors during the Delta and Omicron variant periods. In addition, the study aims to identify the characteristics of countries that had good performances. We analyzed observation data among 29 countries over the first eight weeks during the two periods of Delta and Omicron variant dominance. Data were extracted from open public databases. The Omicron variant caused a lowered mortality rate per 100,000 COVID-19 patients; however, it is still imposing a colossal burden on health care systems. We found the percentage of the population fully vaccinated and high government indices were significantly associated with a better resilience index in both the Delta and Omicron periods. In contrast, the higher death rate of cancers and greater years lived with disability (YLD) caused by low bone density were linked with poor resilience index in the Omicron periods. Over two periods of Delta and Omicron, countries with good performance had a lower death rate from chronic diseases and lower YLD caused by nutrition deficiency and PM2.5. Our findings suggest that governments need to keep enhancing the vaccine coverage rates, developing interventions for populations with chronic diseases and nutrition deficiency to mitigate COVID-19 impacts on these targeted vulnerable cohorts.
Asunto(s)
COVID-19 , Chryseobacterium , Infección Hospitalaria , Infecciones por Flavobacteriaceae , Sepsis , Antibacterianos/uso terapéutico , Infección Hospitalaria/tratamiento farmacológico , Infecciones por Flavobacteriaceae/diagnóstico , Infecciones por Flavobacteriaceae/tratamiento farmacológico , Humanos , Sepsis/tratamiento farmacológicoRESUMEN
Candida albicans (C. albicans) is an opportunistic human pathogen responsible for approximately a half of clinical candidemia. The emerging Candida spp. with resistance to azoles is a major challenge in clinic, suggesting an urgent demand for new drugs and therapeutic strategies. Alpha-enolase (Eno1) is a multifunctional protein and represents an important marker for invasive candidiasis. Thus, C. albicans Eno1 (CaEno1) is believed to be an important target for the development of therapeutic agents and antibody drugs. Recombinant CaEno1 (rCaEno1) was first used to immunize chickens. Subsequently, we used phage display technology to construct two single chain variable fragment (scFv) antibody libraries. A novel biopanning procedure was carried out to screen anti-rCaEno1 scFv antibodies, whose specificities were further characterized. The polyclonal IgY antibodies showed binding to rCaEno1 and native CaEno1. A dominant scFv (CaS1) and its properties were further characterized. CaS1 attenuated the growth of C. albicans and inhibited the binding of CaEno1 to plasminogen. Animal studies showed that CaS1 prolonged the survival rate of mice and zebrafish with candidiasis. The fungal burden in kidney and spleen, as well as level of inflammatory cytokines were significantly reduced in CaS1-treated mice. These results suggest CaS1 has potential of being immunotherapeutic drug against C. albicans infections.
Asunto(s)
Antifúngicos/farmacología , Candida albicans/efectos de los fármacos , Candida albicans/enzimología , Inhibidores Enzimáticos/farmacología , Fosfopiruvato Hidratasa/antagonistas & inhibidores , Anticuerpos de Cadena Única/farmacología , Animales , Evaluación Preclínica de Medicamentos , Ratones , Unión Proteica , Pez CebraAsunto(s)
Antibacterianos/uso terapéutico , Fusobacterium necrophorum/efectos de los fármacos , Síndrome de Lemierre/diagnóstico por imagen , Síndrome de Lemierre/tratamiento farmacológico , Enfermedad Aguda , Diabetes Mellitus Tipo 2/complicaciones , Fusobacterium necrophorum/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/cirugía , Resultado del TratamientoAsunto(s)
Infecciones Comunitarias Adquiridas/etiología , Infecciones Comunitarias Adquiridas/microbiología , Complicaciones de la Diabetes , Pasteurella multocida/patogenicidad , Neumonía/etiología , Neumonía/microbiología , Animales , Animales Domésticos , Antibacterianos/uso terapéutico , Bacteriemia , Infecciones Comunitarias Adquiridas/diagnóstico , Infecciones Comunitarias Adquiridas/terapia , Diabetes Mellitus , Humanos , Masculino , Persona de Mediana Edad , Pasteurella multocida/aislamiento & purificación , Neumonía/diagnóstico , Neumonía/terapiaRESUMEN
Severe falciparum malaria is associated with multiple organ dysfunction and a high rate of fatal outcome. Malaria is a world-wide disease in tropical areas through the bites of vector mosquitoes. Parasitic protozoans introduced by the mosquito's saliva to the blood travel to the liver then mature and reproduce. In humans, malaria is caused by Plasmodium falciparum, P. malariae, P. ovale, P. vivax, and P. knowlesi, and P. falciparum causes most deaths. Typical malaria symptoms include fever, chills, fatigue, headache, nausea, and vomiting. In severe cases, it can cause jaundice, seizures, coma, or death. Jaundice, caused by intravascular hemolysis is a usual complication of malaria, especially in patients with P. falciparum infection. The use of exchange transfusion in malaria is not currently advocated by the Centers of Disease Control and Prevention (CDC) of the United States of America. The role of therapeutic plasma exchange as an adjunctive therapy in malaria has not been widely discussed in the literature. Here, we present a 23-year-old patient with jaundice, acute renal failure, and cerebral involvement who was successfully treated with plasma exchange and hemodialysis.
Asunto(s)
Malaria Falciparum/terapia , Intercambio Plasmático/métodos , Humanos , Ictericia , Diálisis Renal , Insuficiencia Renal , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: We conducted a phase I/II clinical trial to evaluate the safety and immunogenicity of a Madin-Darby canine kidney (MDCK) cell-grown inactivated H7N9 influenza vaccine for pandemic preparedness purposes. METHODS: Between April 7, 2015 and May 27, 2016, healthy adults aged 20-60years were enrolled sequentially in phase I (n=40) and phase II (n=160) from three hospitals in Taiwan and randomized to receive 2 doses of whole-virus H7N9 vaccine (15 or 30µg hemagglutinin antigen (HA) with or without an aluminum hydroxide adjuvant) at 21-day intervals. Safety up to 180days and changes in hemagglutinin inhibition (HI) titers at 21days after each vaccination were determined. RESULTS: Of the 200 randomized subjects, 193 (96.5%) received 2 doses of the study vaccine and were included in the intention-to-treat analysis for safety, and 190 (95%) were included in the per-protocol analysis for immunogenicity. Most adverse events were mild and transient; no death or vaccine-related serious adverse events were reported. Overall, higher immune responses were observed in the groups administered with 30µgHA formulation than in the other two groups administered with 15µgHA formulation. The highest immune response was observed in subjects who received 2 doses of the adjuvanted vaccine containing 30µgHA with HI titer, seroprotection rate, seroconversion rate, and seroconversion factor of 36.2, 64.6%, 64.6% and 5.7, respectively. CONCLUSIONS: Our study demonstrated that the H7N9 influenza vaccine containing 30µgHA with aluminum hydroxide adjuvant was immunogenic and safe in adults aged 20-60years. CLINICALTRIALS.GOV identifier: NCT02436928.
Asunto(s)
Subtipo H7N9 del Virus de la Influenza A/inmunología , Vacunas contra la Influenza/efectos adversos , Vacunas contra la Influenza/inmunología , Gripe Humana/prevención & control , Adyuvantes Inmunológicos/administración & dosificación , Adulto , Hidróxido de Aluminio/administración & dosificación , Animales , Anticuerpos Antivirales/sangre , Técnicas de Cultivo de Célula , Perros , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/patología , Femenino , Voluntarios Sanos , Pruebas de Inhibición de Hemaglutinación , Humanos , Esquemas de Inmunización , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/virología , Células de Riñón Canino Madin Darby , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Taiwán , Tecnología Farmacéutica , Vacunas de Productos Inactivados/administración & dosificación , Vacunas de Productos Inactivados/efectos adversos , Vacunas de Productos Inactivados/inmunología , Adulto JovenAsunto(s)
Adenocarcinoma/complicaciones , Bacteriemia/diagnóstico , Bacteriemia/terapia , Neoplasias del Colon/complicaciones , Endocarditis Bacteriana/etiología , Infecciones Estreptocócicas/diagnóstico , Infecciones Estreptocócicas/terapia , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Bacteriemia/microbiología , Bacteriemia/patología , Cultivo de Sangre , Terapia Combinada , Ecocardiografía Transesofágica , Endocarditis Bacteriana/microbiología , Endocarditis Bacteriana/terapia , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Válvula Mitral/diagnóstico por imagen , Válvula Mitral/cirugía , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Infecciones Estreptocócicas/microbiología , Infecciones Estreptocócicas/patología , Streptococcus sanguis , Taiwán , Resultado del TratamientoAsunto(s)
Coinfección/microbiología , Empiema Pleural/microbiología , Fusobacterium necrophorum , Síndrome de Lemierre/diagnóstico , Mycoplasma pneumoniae , Neumonía por Mycoplasma/diagnóstico , Antibacterianos/uso terapéutico , Tubos Torácicos , Coinfección/diagnóstico , Coinfección/patología , Coinfección/terapia , Terapia Combinada , Empiema Pleural/diagnóstico , Empiema Pleural/patología , Empiema Pleural/terapia , Humanos , Síndrome de Lemierre/microbiología , Síndrome de Lemierre/patología , Síndrome de Lemierre/terapia , Pulmón/microbiología , Pulmón/patología , Masculino , Neumonía por Mycoplasma/microbiología , Neumonía por Mycoplasma/patología , Neumonía por Mycoplasma/terapia , Radiografía , Taiwán , Resultado del Tratamiento , Adulto JovenAsunto(s)
Bacteriemia , Neoplasias Pulmonares/complicaciones , Infecciones por Moraxellaceae , Neumonía Bacteriana , Antibacterianos/uso terapéutico , Bacteriemia/complicaciones , Bacteriemia/diagnóstico , Bacteriemia/tratamiento farmacológico , Bacteriemia/patología , Farmacorresistencia Bacteriana Múltiple , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Técnicas de Diagnóstico Molecular , Moraxella , Infecciones por Moraxellaceae/complicaciones , Infecciones por Moraxellaceae/diagnóstico , Infecciones por Moraxellaceae/tratamiento farmacológico , Infecciones por Moraxellaceae/patología , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/diagnóstico , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/patología , Radiografía , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Taiwán , Resultado del TratamientoAsunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Antifúngicos/uso terapéutico , Terapia Antirretroviral Altamente Activa , Caspofungina/uso terapéutico , Neumonía por Pneumocystis/tratamiento farmacológico , Terapia Recuperativa , Infecciones Oportunistas Relacionadas con el SIDA/diagnóstico , Fármacos Anti-VIH/uso terapéutico , Líquido del Lavado Bronquioalveolar/microbiología , Recuento de Linfocito CD4 , Humanos , Masculino , Persona de Mediana Edad , Pneumocystis carinii/efectos de los fármacos , Pneumocystis carinii/aislamiento & purificación , Neumonía por Pneumocystis/diagnóstico , Neumonía por Pneumocystis/patología , Taiwán , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
BACKGROUND: Candida albicans, a common fungal pathogen that can cause opportunistic infections, is regarded as an apparently asexual, diploid fungus. A parasexual cycle was previously found between homozygotes with opposite mating type-like loci (MTLa/α). Fluconazole-resistant strains had a higher proportion of MTL homozygotes, whereas MTL homozygous C. albicans was found in only about 3.2% of clinical strains. MTL heterozygotes had a low frequency (1.4 × 10-4) of white-opaque switching to MTL homozygotes in nature. METHODS: Here, a reference C. albicans strain (SC5314) was used in a fluconazole-induced assay to obtain standard opaque MTL homozygous strains and first-generation daughter strains from the fluconazole inhibition zone. Further separation methods were employed to produce second- and third-generation daughter strains. Polymerase chain reaction analysis based on MTL genes was used to define MTL genotypes, and microscopic observations, a flow-cytometric assay, and an antifungal E-test were used to compare microbiological characteristics. RESULTS: MTL homozygotes were found at a high frequency (17 of 35; 48.6%) in fluconazole-induced first-generation daughter strains, as were morphological polymorphisms, decreased DNA content, and modified antifungal drug susceptibility. High-frequency MTL homozygosity was identified inside the fluconazole inhibition zone within 24 hours. The DNA content of fluconazole-induced daughter strains was reduced compared with their progenitor SC5314 and standard MTL homozygous strains. CONCLUSION: Treatment with fluconazole, commonly used to treat invasive candidiasis, inhibited the growth of C. albicans and altered its microbiological characteristics. Our results suggest that fluconazole treatment induces the high frequency of loss of heterozygosity and microbiological polymorphism in C. albicans.